Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Cash from Financing Activities (2016 - 2025)

Sanara MedTech (SMTI) has disclosed Cash from Financing Activities for 14 consecutive years, with -$774749.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities fell 105.37% year-over-year to -$774749.0, compared with a TTM value of $7.5 million through Sep 2025, down 58.94%, and an annual FY2024 reading of $17.4 million, up 80.13% over the prior year.
  • Cash from Financing Activities was -$774749.0 for Q3 2025 at Sanara MedTech, up from -$2.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $28.7 million in Q1 2021 and bottomed at -$2.5 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $4.0 million, with a median of -$144409.5 recorded in 2022.
  • The sharpest move saw Cash from Financing Activities tumbled 3475.48% in 2021, then skyrocketed 1919.73% in 2025.
  • Year by year, Cash from Financing Activities stood at -$442525.0 in 2021, then skyrocketed by 31.21% to -$304415.0 in 2022, then surged by 38.94% to -$185888.0 in 2023, then tumbled by 546.06% to -$1.2 million in 2024, then skyrocketed by 35.49% to -$774749.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for SMTI at -$774749.0 in Q3 2025, -$2.5 million in Q2 2025, and $12.0 million in Q1 2025.